The Economist (Intelligence Unit) 2012 - Finding Alignment

Opportunities and Obstacles in the Pharma/CRO Relationship.
A report from the Economist Intelligence Unit. Sponsored by Agilent Technologies. 25 p.This report explores the increasingly critical role of contract research organisations (CROs) in the transformation of the drug discovery and development (D&D) process at pharmaceutical and biotechnology companies.
The Economist Intelligence Unit conducted the survey and analysis and wrote the report. The findings and views expressed in this report do not necessarily refl ect the views of the sponsor. The author was Paul Kielstra. Gilda Stahl edited the report, and Mike Kenny was responsible for layout. We would like to thank all of the executives who participated in the survey and interviews for their valuable time and insight.Interviewees
Executive summary
About the survey
Introduction: rapid growth, evolving challenges
The rise of a bifurcated market and its strategic implications
Disruptive innovation: are CROs agents of change?
Making the most of new relationships
Information technology will be part of the evolutionAppendix: survey results